18F-PSMA-1007 is named as an intervention in 3 current clinical trials in our China, Germany, France, Spain, Italy, Netherlands, Japan and Canada registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Affiliated Hospital of Jiangnan University (1). The most-studied condition is Prostate Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
NCT05520255 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 3 | Recruiting | University of Alberta | Canada |
|
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
NCT06122584 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 3 | Recruiting | ABX advanced biochemical compounds GmbH | Germany, France, Spain, Italy, Netherlands, Japan |
|
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
NCT06723665 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Not applicable | By invitation | Affiliated Hospital of Jiangnan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Affiliated Hospital of Jiangnan University | 1 |
| ABX advanced biochemical compounds GmbH | 1 |
| University of Alberta | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, Germany, France, Spain, Italy, Netherlands, Japan and Canada registers name 18F-PSMA-1007 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Japan and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Affiliated Hospital of Jiangnan University (1), ABX advanced biochemical compounds GmbH (1) and University of Alberta (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how 18F-PSMA-1007 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 18F-PSMA-1007 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 18F-PSMA-1007 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.